|
|
Volumn 15, Issue 4, 2016, Pages 229-230
|
|
The non-small-cell lung cancer drug market
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABEMACICLIB;
ALECTINIB;
ANTINEOPLASTIC AGENT;
ASP 8273;
ATEZOLIZUMAB;
AVELUMAB;
BEVACIZUMAB;
CISPLATIN;
CRIZOTINIB;
DABRAFENIB;
DACOMITINIB;
DOCETAXEL;
DURVALUMAB;
ERLOTINIB;
GEFITINIB;
GEMCITABINE;
NECITUMUMAB;
NIVOLUMAB;
OSIMERTINIB;
PATRITUMAB;
PEMBROLIZUMAB;
PEMETREXED;
PROTEIN TYROSINE KINASE INHIBITOR;
ROCILETINIB;
SELUMETINIB;
TG 4010;
TICILIMUMAB;
TRAMETINIB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VELIPARIB;
DRUG APPROVAL;
DRUG COST;
DRUG MARKETING;
EGFR GENE;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
HUMAN;
NON SMALL CELL LUNG CANCER;
NOTE;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
TREATMENT OUTCOME;
BIOLOGICAL THERAPY;
CANCER STAGING;
CARCINOMA, NON-SMALL-CELL LUNG;
CLASSIFICATION;
ECONOMICS;
LUNG NEOPLASMS;
MARKETING;
MEDICATION THERAPY MANAGEMENT;
PATHOLOGY;
PROCEDURES;
TRENDS;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL THERAPY;
CARCINOMA, NON-SMALL-CELL LUNG;
DRUG APPROVAL;
HUMANS;
LUNG NEOPLASMS;
MARKETING;
MEDICATION THERAPY MANAGEMENT;
NEOPLASM STAGING;
|
|
EID: 84962447606
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2016.42 Document Type: Note |
|
Times cited : (45)
|
|
References (0)
|
